TY  - JOUR

T1  - Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.

JO  - Eur J Health Econ

PY  - 2011/06/24

AU  - Delea TE

AU  - Tappenden P

AU  - Sofrygin O

AU  - Browning D

AU  - Amonkar MM

AU  - Karnon J

AU  - Walker MD

AU  - Cameron D

ED  - 

DO  - DOI: 10.1007/s10198-011-0323-1

VL  - 13

IS  - 5

SP  - 589

EP  - 603

Y2  - 2025/04/05

ER  -